CYP2B6, CYP2A6 and UGT2B7 Genetic Polymorphisms are Predictors of Efavirenz Mid-dose Concentration in HIV-infected Patients

Ítems similars

• CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients
  per: Kwara, Awewura, et al.
  Publicat: (2009)
• Paradoxically Elevated Efavirenz Concentrations in HIV/TB Co-infected Patients with CYP2B6 516TT Genotype on Rifampin-containing Antituberculous Therapy
  per: Kwara, Awewura, et al.
  Publicat: (2011)
• Pharmacokinetics of Efavirenz when Co-administered with Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation
  per: Kwara, Awewura, et al.
  Publicat: (2008)
• Isoniazid Mediates the CYP2B6*6 Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6
  per: Court, Michael H., et al.
  Publicat: (2014)
• Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV Co-infected Ghanaian Patients: UGT2B7*1C is Associated with Faster Zidovudine Clearance and Glucuronidation
  per: Kwara, Awewura, et al.
  Publicat: (2009)